11C-PiB与18F-FC119S在健康受试者、轻度认知障碍患者及阿尔茨海默病患者中用于β淀粉样蛋白成像的头对头比较。
Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
作者信息
Byun Byung Hyun, Kim Byung Il, Park Su Yeon, Ko In Ok, Lee Kyo Chul, Kim Kyeong Min, Kim Yu Kyeong, Lee Jun-Young, Bu Seon Hee, Kim Jung Hwa, Chi Dae Yoon, Ha Jeong Ho, Lim Sang Moo
机构信息
Department of Nuclear Medicine Department of Neurology, Korea Cancer Center Hospital Molecular Imaging Research Center, Korea Institute of Radiological & Medical Sciences Department of Nuclear Medicine Department of Psychiatry and Behavioral Science, College of Medicine, Seoul National University, Boramae Hospital Department of Neurology, Seoul Bukbu Hospital Research Institute of Labeling, FutureChem Co., Ltd Department of Chemistry, Sogang University, Seoul, Republic of Korea.
出版信息
Medicine (Baltimore). 2017 Mar;96(12):e6441. doi: 10.1097/MD.0000000000006441.
As a new beta amyloid (Aβ) positron emission tomography (PET) tracer, F-FC119S has shown higher cortical uptake in patients with Alzheimer's disease (AD) than that in healthy control subjects without adverse effects in a previous preliminary study. The aim of this study was to compare F-FC119S PET and C-PiB PET in healthy control (HC) subjects, mild cognitive impairment (MCI) patients, and AD patients.A total of 48 subjects, including 28 HC subjects, 10 MCI patients, and 10 AD patients, underwent static F-FC119S PET (30 minutes after intravenous [i.v.] injection) and C-PiB PET (40 minutes after i.v. injection) on the same day. Both PET images were visually and quantitatively assessed. Standardized uptake value ratios (SUVRs) were calculated for each brain region using the cerebellar cortex as a reference region.None (0%) of the 28 HC subjects and 4 (40%) of 10 MCI patients had positive scans on both PET images. Of the 10 AD patients, 7 (70%) had positive scans on C-PiB PET while 6 (60%) had positive scans on F-FC119S PET. Overall, 47 (98%) of 48 participants showed identical results based on visual analysis. Cortical SUVR of F-FC119S was higher in AD patients (1.38 ± 0.16), followed by that in MCI patients (1.24 ± 0.10) and in HC subjects (1.14 ± 0.05). Compared with C-PiB PET, F-FC119S PET yielded a higher effect size (d = 2.02 vs. 1.67) in AD patients and a slightly lower effect size (d = 1.26 vs. 1.38) in MCI patients. In HC subjects, the nonspecific binding of F-FC119S to white matter (with the frontal cortex-to-white matter SUV ratio of 0.76) was slightly lower than that of C-PiB (ratio of 0.73). There was a significant linear correlation (slope = 0.41, r = 0.78, P < 0.001) between C-PiB and F-FC119S cortical SUVR.We could safely obtain images similar to C-PiB PET imaging Aβ in the brain using F-FC119S PET. Therefore, F-FC119S might be suitable for imaging Aβ deposition.
作为一种新型的β淀粉样蛋白（Aβ）正电子发射断层扫描（PET）示踪剂，F-FC119S在先前的一项初步研究中显示，与健康对照受试者相比，阿尔茨海默病（AD）患者的皮质摄取更高，且无不良反应。本研究的目的是比较健康对照（HC）受试者、轻度认知障碍（MCI）患者和AD患者中F-FC119S PET与C-PiB PET的情况。
共有48名受试者，包括28名HC受试者、10名MCI患者和10名AD患者，在同一天接受了静态F-FC119S PET（静脉注射后30分钟）和C-PiB PET（静脉注射后40分钟）检查。对两种PET图像进行了视觉和定量评估。使用小脑皮质作为参考区域，计算每个脑区的标准化摄取值比率（SUVR）。
28名HC受试者中无一（0%）在两种PET图像上扫描呈阳性，10名MCI患者中有4名（40%）扫描呈阳性。10名AD患者中，7名（70%）在C-PiB PET上扫描呈阳性，6名（60%）在F-FC119S PET上扫描呈阳性。总体而言，48名参与者中有47名（98%）基于视觉分析显示结果相同。AD患者中F-FC119S的皮质SUVR较高（1.38±0.16），其次是MCI患者（1.24±0.10）和HC受试者（1.14±0.05）。与C-PiB PET相比，F-FC119S PET在AD患者中的效应量更高（d = 2.02对1.67），在MCI患者中的效应量略低（d = 1.26对1.38）。在HC受试者中，F-FC119S与白质的非特异性结合（额叶皮质与白质的SUVR比率为0.76）略低于C-PiB（比率为0.73）。C-PiB与F-FC119S皮质SUVR之间存在显著的线性相关性（斜率 = 0.41，r = 0.78，P < 0.001）。
使用F-FC119S PET我们可以安全地获得与C-PiB PET成像大脑中Aβ相似的图像。因此，F-FC119S可能适用于Aβ沉积成像。
Zotero 插件